- Home
- PRO vs XNCR Comparison
PRO vs XNCR Comparison
Compare PRO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRO
- XNCR
- Stock Information
- Founded
- PRO 1985
- XNCR 1997
- Country
- PRO United States
- XNCR United States
- Employees
- PRO N/A
- XNCR N/A
- Industry
- PRO EDP Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- PRO Technology
- XNCR Health Care
- Exchange
- PRO Nasdaq
- XNCR Nasdaq
- Market Cap
- PRO 1.1B
- XNCR 1.1B
- IPO Year
- PRO 2007
- XNCR 2013
- Fundamental
- Price
- PRO $23.05
- XNCR $14.71
- Analyst Decision
- PRO Buy
- XNCR Buy
- Analyst Count
- PRO 8
- XNCR 11
- Target Price
- PRO $26.46
- XNCR $24.20
- AVG Volume (30 Days)
- PRO 1.6M
- XNCR 1.5M
- Earning Date
- PRO 10-27-2025
- XNCR 11-06-2025
- Dividend Yield
- PRO N/A
- XNCR N/A
- EPS Growth
- PRO N/A
- XNCR N/A
- EPS
- PRO N/A
- XNCR N/A
- Revenue
- PRO $351,682,000.00
- XNCR $146,929,000.00
- Revenue This Year
- PRO $10.33
- XNCR $22.09
- Revenue Next Year
- PRO $10.76
- XNCR N/A
- P/E Ratio
- PRO N/A
- XNCR N/A
- Revenue Growth
- PRO 8.92
- XNCR N/A
- 52 Week Low
- PRO $13.61
- XNCR $6.92
- 52 Week High
- PRO $29.84
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- PRO 79.87
- XNCR 61.57
- Support Level
- PRO $22.99
- XNCR $12.17
- Resistance Level
- PRO $23.08
- XNCR $15.50
- Average True Range (ATR)
- PRO 0.05
- XNCR 1.25
- MACD
- PRO -0.24
- XNCR -0.08
- Stochastic Oscillator
- PRO 77.42
- XNCR 78.41
About PRO PROS Holdings Inc.
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.